Cara Therapeutics (CARA) 10-K2023 FY Annual report

Filed: 6 Mar 24, 4:16pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: adware, AI, air, allodynia, annum, Atlantic, attack, attendant, attrition, automated, characteristic, chosen, codified, compression, conflict, contrast, credential, CY, dark, deceptive, deep, deficient, degeneration, degenerative, degradation, delist, delisting, departure, deploying, destruction, deviate, DFK, difelikfelin, Difelkefalin, diligence, disaster, discharge, draft, East, EEA, elapsed, email, emission, encryption, entrapment, environment, escalate, excl, exempt, exploited, Extortion, factor, fake, fiber, flammable, Florida, foreclose, foreclosure, forensic, greatest, ground, guaranty, hardware, harvesting, HCR, HCRX, HD, hosted, hosting, hyperesthesia, hyperpigmented, hypothesia, Imputation, imputed, incl, inconsistent, inquiry, instability, intelligence, Interagency, intercompany, Labour, lender, levied, Lisa, manual, MHMD, Middle, military, Ministry, mis, misrepresentative, molecule, Moltke, mono, monumental, morale, musculoskeletal, necessitate, notified, notify, notifying, organizational, Overnight, overrepresented, paresthesia, pathophysiology, phishing, potency, promptly, reallocate, reallocated, recourse, regain, remitted, repaid, restart, retaliatory, roll, rollover, rubbing, segregation, server, SIP, sizable, SLJ, SOFR, software, SPC, spine, sterling, stuffing, subgroup, subscribing, subsection, subsidiary, sue, SVP, Syringe, Taiwan, talent, threat, unexpectedly, unfair, unlawful, vendor, von, Washington, waste, web, Welfare, whichever, workforce

Removed: abrocitinib, accident, AD, adaptive, advice, agitation, altered, analgesia, anxiety, apportioned, assigning, baricitinib, bile, biologic, biomarker, Bipartisan, blinded, blood, bloodstream, breakdown, breakthrough, burden, cannabinoid, cleanup, clinically, coding, compel, complexity, concentrating, conditional, considerably, contracting, correlate, crisaborole, death, defining, deployment, dermatologic, designate, diagnosed, diarrhea, disability, disfavor, dispensed, distressing, disturbance, dupilumab, Dupixent, dysphoria, ease, eating, efficient, electrical, electrolyte, elevated, elevation, elicit, emergent, emotional, endocrine, engineering, entrusting, essential, estimating, Eucrisa, evolution, exacerbation, excreted, expedite, experiencing, facial, feeling, fluid, Foundation, fragmented, franchise, fulfillment, gabapentin, generating, generically, guide, half, halt, harrison, heart, hematologic, highlighted, holding, hormone, hospital, hypernatremia, importance, incidence, inexpensive, injectable, inpatient, insolvency, interacting, intravascular, investigative, IQVIA, irritating, JAK, jr, KARE, lebrikizumab, leverage, liaison, licensure, liver, lump, MAA, malfunction, mark, mast, mental, minimizing, misappropriation, morbidity, multicenter, multitude, nalfurafine, naltrexone, narcotic, nemolizumab, nephrology, nondeductible, nonselective, notification, observation, occupy, opt, organic, outsource, overcoming, pandemic, partnering, passage, PDMA, PDUFA, pharmacological, physiological, planning, poorly, possession, postoperative, postural, Poverty, prespecified, prolactin, Prolonged, propose, psychiatric, psychosocial, radioactive, rating, receptive, reflex, Remitch, renovation, reproduce, rescind, resist, resumed, rifampin, robust, satisfied, scientifically, serum, skin, social, Society, sodium, somnolence, sophisticated, stopping, studying, superior, supervisory, supported, symptom, tachycardia, tenant, terrorism, thoracic, threaten, timeframe, Toray, tort, toxic, transient, uniform, untapped, upadacitinib, urination, usage, utility, utilize, utilizing, UVB, vomiting, warehouse, widely

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated CARA transcripts

CARA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATIONS OF

CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

OF CARA THERAPEUTICS, INC.

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Cara Therapeutics, Inc. (the "Company") for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Christopher Posner, Chief Executive Officer of the Company, and Ryan Maynard, Chief Financial Officer of the Company, each hereby certifies, pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), that, to the best of his knowledge, based upon a review of the Report:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ CHRISTOPHER POSNER
Name:	Christopher Posner
Title:	Chief Executive Officer (Principal Executive Officer)
Date:	March 6, 2024


/s/ RYAN MAYNARD
Name:	Ryan Maynard
Title:	Chief Financial Officer (Principal Financial Officer)
Date:	March 6, 2024

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Cara Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.